智通财经APP讯，昊海生物科技(06826)发布公告，于2025年9月18日该公司斥资64.92万港元回购2.35万 股，回购价格为每股27.60-27.72港元。 ...

FF305 第 1 頁 共 7 頁 v 1.3.0 呈交日期： 2025年9月18日 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | | 10,000 | % | HKD | 27.68 | | | 變動日期 | 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | | 18,400 | % | HKD | 28 | | | 變動日期 | 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | | 23,500 | 0.0103 % | HKD | 27.63 | | | 變動日期 | 2025年9月18日 | | | | | | 2. 股份分類 | 普通股 | A 股份類別 | | 於香港聯交所上市 | 否 | | ...

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) is facing potential regulatory penalties due to insider trading allegations against its controlling shareholder Jiang Wei, although the company asserts that this matter will not significantly impact its operations or financials [1][3]. Group 1: Company Structure and Shareholding - Jiang Wei and his spouse You Jie are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [3]. - The regulatory penalty is directed solely at Jiang Wei, and the company clarifies that the issue is unrelated to its business operations [3]. Group 2: Business Overview and Financial Performance - Haohai Biological is a prominent producer of hyaluronic acid in China, operating in four main sectors: aesthetic medicine, ophthalmology, orthopedics, and hemostasis [3]. - In 2024, the revenue breakdown by product category shows that aesthetic medicine accounts for 44.30%, ophthalmic products 31.79%, and orthopedic products 16.92% [3]. - The ophthalmology segment is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [3]. - For the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [3].

Core Viewpoint - Haohai Biological Technology (688366.SH) is facing challenges due to a decline in revenue across multiple product lines, while the investigation of its controlling shareholder for insider trading is stated to have no significant impact on the company's operations or finances [1][2]. Financial Performance - For the first half of 2024, Haohai Biological reported a revenue of 1,304.40 million yuan, a year-on-year decrease of 7.12% [2]. - The main business revenue was 1,297.55 million yuan, down 7.52% year-on-year [2]. - Revenue from medical beauty and wound care products was 575.45 million yuan, a decline of 9.31% [2]. - Revenue from ophthalmic products fell by 18.61% to 367.54 million yuan [2]. - Orthopedic product revenue decreased by 2.58% to 226.81 million yuan [2]. - Notably, revenue from anti-adhesion and hemostatic products increased by 59.61% to 110.39 million yuan, although this segment accounted for only 8.51% of total revenue [2]. - The net profit attributable to shareholders was 211.07 million yuan, down 10.29% year-on-year [2]. - The net profit excluding non-recurring gains and losses was 204.21 million yuan, a decrease of 11.35% [2]. - The overall gross margin for the first half was 70.17%, remaining stable compared to 70.51% in the previous year [2]. Research and Development - Haohai Biological's R&D expenses for the first half of 2024 were 98.40 million yuan, a decrease of 21.53% year-on-year [3]. - R&D expenses accounted for 7.54% of revenue, down from 8.93% in the same period last year [3]. - The reduction in R&D spending is attributed to several core projects entering late clinical trial or registration review stages, leading to a temporary decrease in direct labor costs and materials [3].

Core Viewpoint - The announcement regarding the administrative penalty against Jiang Wei, a controlling shareholder of Shanghai Haohai Biological Technology Co., Ltd., is significant as it stems from an insider trading investigation by the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Company Overview - Shanghai Haohai Biological Technology Co., Ltd. is a well-known hyaluronic acid producer in China, operating in four major fields: medical aesthetics, ophthalmology, orthopedics, and hemostasis [4]. - The company is recognized as one of the "three giants" in the Chinese hyaluronic acid market, alongside Huaxi Biological and Aimeike [4]. Group 2: Shareholding Structure - Jiang Wei and his spouse, You Jie, are the actual controllers of Haohai Biological, holding a combined 45.82% of the company's shares as of March 2025, with Jiang Wei owning 28.53% and You Jie 17.29% [4]. Group 3: Financial Performance - In the first half of 2025, the company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit of 211 million yuan, down 10.29% year-on-year [5]. - For 2024, the revenue from the medical aesthetics segment is projected to account for 44.30% of total revenue, while ophthalmology products will contribute 31.79%, and orthopedics will make up 16.92% [4]. - The ophthalmology business is expected to see a revenue decline of 7.6% to 858 million yuan due to the impact of bulk procurement of artificial lenses [4].

Core Viewpoint - The core issue revolves around Jiang Wei, a significant shareholder and actual controller of Hyaluronic Acid giant Haohai Biological Technology, receiving a notice of administrative penalty from the China Securities Regulatory Commission for suspected insider trading. The company asserts that the matter is unrelated to its operations and is solely a personal issue concerning Jiang Wei [1]. Company Summary - Haohai Biological Technology announced that Jiang Wei, one of its major shareholders and actual controllers, has been penalized by the China Securities Regulatory Commission for alleged insider trading [1]. - The company emphasized that the penalty pertains to Jiang Wei as an individual and does not involve the company itself [1]. - Although Jiang Wei founded Haohai Biological Technology, he has largely remained behind the scenes and does not actively participate in the company's operations [1]. - Jiang Wei has established a shareholding structure that allows him to maintain control over Haohai Biological Technology, and he has received over 250 million yuan in dividends from the company during its six years as a publicly listed entity [1]. Industry Context - The incident highlights the ongoing scrutiny of insider trading practices within the biotechnology sector in China, particularly among companies with significant market presence like Haohai Biological Technology [1]. - The company's chairman, Hou Yongtai, previously stated that Jiang Wei is primarily an investor who enjoys trading stocks, but he does not engage in trading Haohai Biological Technology's shares [1].

Core Viewpoint - The announcement regarding the insider trading investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology Co., Ltd., has raised concerns among investors about the company's future, despite the company's claims that the incident is unrelated to its operations [1][2]. Group 1: Company Background - Haohai Biological Technology was founded in 2007 and has evolved into a technology-driven enterprise engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on aesthetic medicine and wound care, ophthalmology, and orthopedic products [5]. - The company was listed on the Hong Kong Stock Exchange in April 2015 and later on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [5]. Group 2: Shareholder Structure - Jiang Wei and You Jie are the controlling shareholders, holding 28.53% and 17.29% of the shares, respectively, making them the first and second largest shareholders [3]. - Jiang Wei is also the ultimate beneficiary of a partnership that holds 1% of the company's shares, indicating a significant influence over the company's governance [3]. Group 3: Financial Performance - In 2024, Haohai Biological reported revenue of 2.698 billion yuan, a mere 1.64% increase compared to previous years, indicating a significant slowdown in growth [5]. - The company experienced a decline in revenue and net profit in the first half of 2025, with revenue dropping by 7.12% to 1.304 billion yuan and net profit decreasing by 10.29% to 211 million yuan [6]. - The three main business segments—medical aesthetics, ophthalmology, and orthopedics—saw revenue declines of 9.31%, 18.61%, and 2.58%, respectively, in the first half of 2025 [6]. Group 4: Management and Strategy - The company's operational management is handled by a professional team led by key figures such as Hou Yongtai and Wu Jianying, who hold significant positions within the company [3]. - The company has reported a 21.53% decrease in R&D expenses, with the R&D expense ratio falling to 7.54% from 8.93% in the previous year, attributed to the completion of core projects [6].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84 万股。 ...

昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84万股。 ...